2-year maintenance of response with tralokinumab in moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial - Blauvelt, A; Lacour, J -P; Toth, D; Langley, R; Warren, R; Pinto, P Herranz; Pink, A; Simpson, Eric; Peris, Ketty; Wollenberg, Andreas; Le Gjerum; Fangel, Stine; et al. (BRITISH JOURNAL OF DERMATOLOGY, 2022)